Biologics Contract Manufacturing Asia 2025 is the premier gathering for CDMOs, biopharma leaders, and industry stakeholders driving innovation in biologics production.
With APAC’s biologics sector experiencing rapid growth, major players like Samsung Biologics, WuXi Biologics, Chime Biologics, and Lotte Biologics are expanding capabilities in monoclonal antibodies, cell and gene therapies, and next-gen biologics. Key topics include AI-driven biomanufacturing, process automation, single-use technologies, continuous bioprocessing, cost-efficiency, facility scaling, and regulatory trends.
The conference will also highlight breakthrough innovations in RNA-based biologics, novel therapeutics, and AI-powered process optimization, shaping the future of biologics manufacturing in APAC.
Biologics Contract Manufacturing Asia 2025 (#BCMA) offers unparalleled opportunities for knowledge-sharing, networking, and innovation, shaping the future of biologics manufacturing in APAC and beyond.
